Cosmos Health

Cosmos Health Gross Margin

The Gross Margin of Cosmos Health (COSM) as of Nov 16, 2026 is 12.10 %. In the previous year, Gross Margin was 7.92 % — a change of 52.71% (higher).

Gross Margin

12.10 %

YoY

52.71%

Last updated:

Gross Margin of Cosmos Health is 2025 12.10 % . Gross Margin of Cosmos Health was 2024 7.92 % . It decreases by 52.71% higher compared to the previous year.

For Cosmos Health, the gross margin of 12.1% is down versus 14.8% a few years ago.

The Cosmos Health Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
6.50 USD
Jan 1, 2019
9.23 USD
Jan 1, 2020
14.55 USD
Jan 1, 2021
14.81 USD
Jan 1, 2022
11.83 USD
Jan 1, 2023
8.15 USD
Jan 1, 2024
7.92 USD
Jan 1, 2025
12.10 USD
The Cosmos Health Gross Margin history
YEARGross MarginYoY
12.10 %+52.71%
7.92 %-2.79%
8.15 %-31.13%
11.83 %-20.12%
14.81 %+1.82%
14.55 %+57.61%
9.23 %+42.11%
6.50 %-0.35%
6.52 %-26.74%
8.90 %-3.06%
9.18 %-90.74%
99.07 %+9,807.31%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmos Health Stock analysis

What does Cosmos Health do? Cosmos Health Inc generates revenue through the importation, exportation, distribution, and sale of branded pharmaceuticals, over-the-counter medicines, and generic pharmaceuticals. The company leverages its subsidiary Amplerissimo Ltd., which provides data mining, statistical data analysis, research, and consulting services including credit risk analysis, marketing management, and business management software consulting. SkyPharm S.A., a subsidiary of Amplerissimo, trades branded and generic pharmaceutical products across the European Union member states, contributing to the company's revenue streams. Clients include sectors requiring pharmaceutical distribution, consulting services, and EU market access for medicines. Amplerissimo's services target businesses needing data-driven insights, credit management, and strategic consulting, while SkyPharm serves the European pharmaceutical market with a focus on branded and generic products. The company's revenue model combines direct product sales with specialized consulting services, catering to both domestic and international clients in the pharmaceutical industry. This dual approach allows Cosmos Health Inc to address diverse market needs through its subsidiaries and core operations. The firm's primary buyers are pharmaceutical distributors, healthcare providers, and businesses seeking consulting services for market expansion, data analysis, and credit management. Amplerissimo's consulting services support clients in sectors requiring strategic planning, while SkyPharm's trading activities serve EU-based pharmaceutical companies and distributors. Cosmos Health Inc's revenue is derived from product sales and service contracts, with no mention of additional revenue streams beyond the described operations. Cosmos Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmos Health stock

Gross Margin of Cosmos Health is 12.10 % in 2025.

Gross Margin of Cosmos Health changed from 7.92 % to 12.10 %, representing a 52.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Cosmos Health since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Cosmos Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cosmos Health

All Key Metrics — Cosmos Health